Ticker

Oruka Therapeutics, Inc. (NASDAQ: ORKA - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday after HC Wainwright raised their price target on the stock from $40.00 to $70.00. HC Wainwright currently has a buy rating on the stock. Oruka Therapeutics traded as high as $65.64 and last traded at $66.1010,

Secure Asset Management LLC purchased a new position in Oruka Therapeutics, Inc. (NASDAQ: ORKA) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 81,664 shares of the company's stock, valued at approximately $2,475,000. Secure Asset Management LLC owned approximately 0.17% of

Shares of Oruka Therapeutics, Inc. (NASDAQ: ORKA - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average 12

The average of price targets set by Wall Street analysts indicates a potential upside of 41.5% in Oruka Therapeutics, Inc. (ORKA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Avoro Capital Advisors LLC purchased a new stake in Oruka Therapeutics, Inc. (NASDAQ: ORKA) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 1,333,340 shares of the company's stock, valued at approximately $25,640,000. Oruka Therapeutics accounts for about 0.3% of Avoro Capital Advisors LLC's